Accelerating Medicines Partnership® SCHIZOPHRENIA
Participating in the Study
Participating in the Accelerating Medicines Partnership (AMP®) Schizophrenia (SCZ) research study will allow scientists to understand better what happens to young people at clinical high risk for psychosis. By knowing more, scientists can improve mental health interventions and the support provided to young people.

Purpose of the Study

When young people seek support for a mental health problem, it’s important for clinicians to be able to predict whether the problem will get better, stay the same, or get worse. It’s also important for clinicians to know what kinds of treatments will be most helpful. 

This research will study young people who are at clinical high risk for psychosis in order to find characteristics that are linked with long-term health. The aim is to create tools that can enable testing of novel interventions for individuals at clinical high risk.

In order to meet these aims, the researchers will recruit 2,500 participants across North America, South America, Australia, Asia, and Europe. Researchers will collect a wide range of information about the participants’ symptoms, behavior, family history, thinking processes, and biology. 

The study will also include young people who are not experiencing any clinical high risk symptoms. This will help researchers to make better predictions about who will experience certain outcomes.

Last Reviewed on May 2, 2022